He found them entirely depleted in an area called the striatum. Reasoning that symptoms could be caused by lack of dopamine and thus reversed by replacing it, he joined forces, in , with neurologist Walter Birkmayer to inject L -DOPA into 20 severely parkinsonian patients.
This achieved miraculous, if temporary, effects: for a few hours, their rigid limbs melted into movement. His New England Journal of Medicine paper, reporting a successful two-year study on 28 patients, made the pages of Time magazine. Remarkably, no more efficacious drug has yet been developed, although there have been useful attempts.
With L -DOPA, a good two-thirds of patients develop mild or severe dyskinesias following several years of therapy, after which the disturbing on—off phenomenon also kicks in. Ideally, L -DOPA would be packaged and delivered in a form that avoided these side effects, but the molecule turned out to be a pharmacologist's nightmare. It looks small and innocent, but has an incompliant chemistry and unhelpful metabolism.
For one thing, it is removed rapidly by enzymes in the blood where it has a half-life of around an hour. It was relatively easy to improve on this by judicious use of enzyme inhibitors. L -DOPA is converted to dopamine by the aromatic amino-acid decarboxylase enzyme in the blood. This source of dopamine causes peripheral side effects like nausea and reduces the amount of L -DOPA available to cross into the brain. Since the late s, L -DOPA has been given together with carbidopa, or another inhibitor of this enzyme, stretching its half-life in the blood to 90 minutes.
More recently, clinicians have taken to adding inhibitors of dopamine's two breakdown enzymes, catechol- O -methyl-transferase COMT and monoamine oxidase MAO , to the therapeutic mix, extending the duration of L -DOPA's effects further. This modestly extended half-life is of little help when it comes to problems after long-term use. It is taken up into dopaminergic nerve terminals where it is briefly stored before being converted into dopamine and released upon nerve stimulation. The nerve terminals thus provide a short-term buffering of the variable blood levels, allowing the drug effect to be maintained between doses.
As the disease progresses and more dopaminergic nerve terminals are destroyed, however, this buffering capacity shrinks, and the therapeutic effect of L -DOPA starts to reflect its blood levels. Why this should promote dyskinesias is not certain, but a prevailing theory holds that it is because the dopamine-depleted brain becomes more sensitive to external dopamine in compensation and thus overreacts to the dopamine generated from L -DOPA.
The on—off effects are also not entirely understood because the off times do not always coincide with low blood levels of L -DOPA. What is clear is that stabilizing the blood levels greatly ameliorates these undesirable effects. And not just because no-one can comfortably live attached to a drip; L -DOPA is also poorly soluble in water so the quantities needed for therapeutic effect are enormous, and it irritates veins and soft tissues.
Once again, however, L -DOPA's physiochemical properties let it down: it does not pass easily through the skin. As yet, no patch is on the market. Most alternative approaches to oral delivery — like nasal or rectal — have also failed. L -DOPA is absorbed in an inconveniently short stretch of the intestine — the duodenum and upper jejunum, just below the stomach — limiting the time available for any formulation.
Absorption is also limited by the regularity with which the stomach empties into the intestine, and this can be erratic in Parkinson's disease patients. Many ingenious approaches are being tried to get around these problems, like attaching L -DOPA to materials that are actively retained in the stomach and letting it seep slowly into the duodenum.
A system of microtablets is also under development, comprising tiny L -DOPA pills in a special dispenser, to allow more frequent but smaller doses according to individual need. One solution for continuous dopaminergic stimulation is the so-called Duodopa system.
It was approved for use in advanced Parkinson's disease in several European countries in and is currently being fast tracked by the US Food and Drug Administration. When levodopa is taken with carbidopa, much lower doses of levodopa can be consumed and side effects such as nausea are minimized. George C.
Cotzias back in the s. This week I will address some of these common questions that have been sent to us by readers like you. If you have questions or a blog topic to suggest , let us know! In general, there is no downside to postponing levodopa to treat a tremor that is not affecting function. Please discuss with your neurologist or physical therapist to determine if you are able to exercise effectively and up to your maximal capabilities while unmedicated.
If you are not able to exercise maximally when untreated, then you should consider starting medication. It is best at treating the slowness and stiffness of PD, but in many cases, treats the tremor as well. The answer is, sometimes. Because tremor is present at rest and often goes away when the person is using the limb, a tremor can be more of a nuisance than a source of disability. It should also be noted, that for people whose tremor does not improve with medication, deep brain stimulation DBS can be considered as a treatment option.
For more information on this procedure, watch our Deep Brain Simulation webinar. This is very beneficial because it gives doctors many treatment options as they try to find the best formulation for each particular patient.
Take a look at our offerings for more information on PD meds. Your neurologist will try to find a dose that helps your PD symptoms, but does not cause side effects. You should discuss this problem with your neurologist who may consider changing your medication dosage. It sounds like these movements may be levodopa-induced dyskinesias , a side effect of the levodopa, which causes extraneous, dance-like movements.
The first question to ask is: are the movements bothering your husband or causing him to be more imbalanced? He may need his current dose to achieve mobility. It is therefore important to let your doctor know if you are experiencing wearing-off. Your medicine effectively tops up dopamine levels within your brain for several hours, so most people get effective symptom control with three doses per day.
The dopamine level in your brain gradually declines, which makes it harder for each dose of levodopa to prevent symptoms re-emerging. Doses of levodopa are effective for a shorter time. When this happens, most people start to experience fluctuations in symptom control throughout the day. For some people, wearing-off can begin within one to two years of starting levodopa therapy; for others, levodopa may remain effective for five years or more.
Many people find that problems with movement motor symptoms return during wearing-off, but other symptoms non-motor can also occur.
Your doctor can help you manage wearing-off by adding to or changing your medication, dose or schedule.
0コメント